QRS widening rates and genetic polymorphisms of matrix metalloproteinases in a cohort of patients with chronic heart failure

Canadian Journal of Cardiology

Volumn 30, Issue 3, 2014, Pages 345-351

  Olsen, Virgilio ^a   Rohde, Luis E ^a,b   Beck da Silva, Luis ^a,b   Santos, Kátia G ^a,b,c   Biolo, Andréia ^a,b   Clausell, Nadine ^a,b   Andrades, Michael ^a,b  

^a HOSPITAL DE CLÍNICAS DE PORTO ALEGRE   (Brazil)

^b FEDERAL UNIVERSITY OF RIO GRANDE DO SUL   (Brazil)

^c UNIVERSIDADE LUTERANA DO BRASIL   (Brazil)

Author keywords

[No Author keywords available]

Indexed keywords

BRAZIL; DNA; ELECTROCARDIOGRAPHY; FEMALE; FOLLOW-UP STUDIES; GENETIC PREDISPOSITION TO DISEASE; GENOTYPE; HEART FAILURE; HUMANS; MALE; MATRIX METALLOPROTEINASES; MIDDLE AGED; POLYMERASE CHAIN REACTION; POLYMORPHISM, GENETIC; PROGNOSIS; PROSPECTIVE STUDIES; SURVIVAL RATE; VENTRICULAR FUNCTION, LEFT;

EID: 84894245103     PISSN: 0828282X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.cjca.2013.11.014     Document Type: Article

References (31)

1. Rubart M., Zipes D.P. Genesis of Cardiac Arrhythmias: Electrophysiological Considerations. Braunwald's Heart Disease: A Textbook of Cardiovascular Medicine 2008, 727-761. Saunders, Philadelphia. E. Braunwald (Ed.).
2. Beck-da-Silva L., Goldraich L., Bonzanini L., et al. Pulse pressure and QRS width evaluation as an inexpensive tool for heart failure assessment. Congest Heart Fail 2009, 15:222-227.
3. Kalra P.R., Sharma R., Shamim W., et al. Clinical characteristics and survival of patients with chronic heart failure and prolonged QRS duration. Int J Cardiol 2002, 86:225-231.
4. Grigioni F., Carinci V., Boriani G., et al. Accelerated QRS widening as an independent predictor of cardiac death or of the need for heart transplantation in patients with congestive heart failure. JHeart Lung Transplant 2002, 21:899-902.
5. Shamim W., Yousufuddin M., Cicoria M., et al. Incremental changes in QRS duration in serial ECGs over time identify high risk elderly patients with heart failure. Heart 2002, 88:47-52.
6. Gajarsa J.J., Kloner R.A. Left ventricular remodeling in the post-infarction heart: a review of cellular, molecular mechanisms, and therapeutic modalities. Heart Fail Rev 2011, 16:13-21.
7. Medley T.L., Kingwell B.A., Gatzka C.D., Pillay P., Cole T.J. Matrix metalloproteinase-3 genotype contributes to age-related aortic stiffening through modulation of gene and protein expression. Circ Res 2003, 92:1254-1261.
8. Langers A.M., Verspaget H.W., Hommes D.W., Sier C.F. Single-nucleotide polymorphisms of matrix metalloproteinases and their inhibitors in gastrointestinal cancer. World J Gastrointest Oncol 2011, 3:79-98.
9. Velho F.M., Cohen C.R., Santos K.G., et al. Polymorphisms of matrix metalloproteinases in systolic heart failure: role on disease susceptibility, phenotypic characteristics, and prognosis. JCard Fail 2011, 17:115-121.
10. Mizon-Gerard F., de Groote P., Lamblin N., et al. Prognostic impact of matrix metalloproteinase gene polymorphisms in patients with heart failure according to the aetiology of left ventricular systolic dysfunction. Eur Heart J 2004, 25:688-693.
11. Tang L.J., Chen X.F., Zhu M., et al. Matrix metalloproteinase-1, -3, and -9 gene polymorphisms and the risk of idiopathic dilated cardiomyopathy in a Chinese Han population. Clin Biochem 2007, 40:1427-1430.
12. Hua Y., Song L., Wu N., et al. Polymorphisms of MMP-2 gene are associated with systolic heart failure prognosis. Clin Chim Acta 2009, 404:119-123.
13. Lahiri D.K., Nurnberger J.I. Arapid non-enzymatic method for the preparation of HMW DNA from blood for RFLP studies. Nucleic Acids Res 1991, 19:5444.
14. Dhar R., Alsheikh-Ali A.A., Estes N.A.M., et al. Association of prolonged QRS duration with ventricular tachyarrhythmias and sudden cardiac death in the Multicenter Automatic Defibrillator Implantation Trial II (MADIT-II). Heart Rhythm 2008, 5:807-813.
15. Yerra L., Anavekar N., Skali H., et al. Association of QRS duration and outcomes after myocardial infarction: the VALIANT trial. Heart Rhythm 2006, 3:313-316.
16. Katritsis D.G., Siontis K.C., Bigger J.T., et al. Effect of left ventricular ejection fraction and QRS duration on the survival benefit of implantable cardioverter-defibrillators: Meta-analysis of primary prevention trials. Heart Rhythm 2013, 10:200-206.
17. Exner D.V., Birnie D.H., Moe G., et al. Canadian Cardiovascular Society guidelines on the use of cardiac resynchronization therapy: evidence and patient selection. Can J Cardiol 2013, 29:182-195.
18. Song B.G., Yang H.S., Hwang H.K., et al. Correlation of electrocardiographic changes and myocardial fibrosis in patients with hypertrophic cardiomyopathy detected by cardiac magnetic resonance imaging. Clin Cardiol 2013, 36:31-35.
19. Sheridan D.J., Culling W., Penny W.J. Electrophysiological disturbances associated with acute myocardial infarction. Eur Heart J 1986, (7 suppl B):11-18.
20. Mazzoleni A., Curtin M.E., Wolff R., Reiner L., Somes G. On the relationship between heart weights, fibrosis, and QRS duration. JElectrocardiol 1975, 8:233-236.
21. Royer A., van Veen T.A.B., Le Bouter S., et al. Mouse model of SCN5A-linked hereditary Lenègre's disease: age-related conduction slowing and myocardial fibrosis. Circulation 2005, 111:1738-1746.
22. Spinale F.G., Coker M.L., Heung L.J., et al. Amatrix metalloproteinase induction/activation system exists in the human left ventricular myocardium and is upregulated in heart failure. Circulation 2000, 102:1944-1949.
23. Rohde L.E., Ducharme A., Arroyo L.H., et al. Matrix metalloproteinase inhibition attenuates early left ventricular enlargement after experimental myocardial infarction in mice. Circulation 1999, 99:3063-3070.
24. Cadete V.J., Arcand S.A., Chaharyn B.M., et al. Matrix metalloproteinase-2 is activated during ischemia/reperfusion in a model of myocardial infarction. Can J Cardiol 2013, 29:1495-1503.
25. Martin T.N., Penney D.E., Smith J.A., et al. Matrix metalloproteinase-1 promoter polymorphisms and changes in left ventricular volume following acute myocardial infarction. Am J Cardiol 2004, 94:1044-1046.
26. Ye S., Gale C.R., Martyn C.N. Variation in the matrix metalloproteinase-1 gene and risk of coronary heart disease. Eur Heart J 2003, 24:1668-1671.
27. Wilson E.M., Moainie S.L., Baskin J.M., et al. Region- and type-specific induction of matrix metalloproteinases in post-myocardial infarction remodeling. Circulation 2003, 107:2857-2863.
28. Vasku A., Goldbergova M., Holla L.I., et al. Two MMP-2 promoter polymorphisms (-790T/G and -735C/T) in chronic heart failure. Clin Chem Lab Med 2003, 41:1299-1303.
29. Price S.J., Greaves D.R., Watkins H. Identification of novel, functional genetic variants in the human matrix metalloproteinase-2 gene: role of Sp1 in allele-specific transcriptional regulation. JBiol Chem 2001, 276:7549-7558.
30. Zhang B., Ye S., Herrmann S.M., et al. Functional polymorphism in the regulatory region of gelatinase B gene in relation to severity of coronary atherosclerosis. Circulation 1999, 99:1788-1794.
31. Zhi H., Wang H., Ren L., et al. Functional polymorphisms of matrix metallopeptidase-9 and risk of coronary artery disease in a Chinese population. Mol Biol Rep 2010, 37:13-20.